研究MET蛋白作为胰腺管腺癌中的瘤基因酶的功能和向:一个微阵列数据集成
Nahid Askari1, Morteza Hadizadeh2, Mohammad Sina3
1Department of Biotechnology, Institute of Sciences and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran.
BioImpacts : BI
|March 31, 2025
概括
这项研究确定了黄糖三叶草中的两种抗癌化合物用于胰腺癌药物开发. 需要进一步的研究来确认它们对胰腺管道腺癌的有效性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物信息学是一种生物信息学.
背景情况:
- 胰腺管腺癌 (PDAC) 是一种致命的癌症,治疗选择有限.
- 激酶蛋白对细胞功能至关重要,并代表潜在的治疗点.
研究的目的:
- 在PDAC中识别差异表达的激酶 (DE-激酶).
- 选植物化学物质对潜在的抗癌药物开发与PDAC相关的激酶.
主要方法:
- 微阵列数据集成用于在PDAC中识别DE-Kinases.
- 来自Melilotus officinalis的植物化学物质在体选和分子对接中与选定的激酶对抗.
- 分子动力学模拟以评估潜在候选药物的稳定性.
主要成果:
- MET,PAK3和PDK4被确定为DE-基因酶,MET与患者存活率有显著的关联.
- 来自Melilotus officinalis的两种无毒植物化学物质 - - 迪库马罗和梅洛原蛋白 - - 显示出与MET的高结合亲和力.
- 分子动力学模拟证实了dicumarol和melilotigenin的稳定性和运动性.
结论:
- 迪库马罗和梅洛基因因是新型PDAC药物开发的有希望的候选者.
- 需要进行实验验证,以确认这些已识别的植物化学品的治疗疗效.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:22PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K